Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction

Similar documents
Central pressures and prediction of cardiovascular events in erectile dysfunction patients

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

CVD risk assessment using risk scores in primary and secondary prevention

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

ASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION

Central Pressures and Prehypertension

Coronary artery disease (CAD) risk factors

Methods. Background and Objectives STRADIVARIUS

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece

Cho et al., 2009 Journal of Cardiology (2009), 54:

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Cardiovascular Diseases in CKD

surtout qui n est PAS à risque?

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Arterial function and longevity Focus on the aorta

The Diabetes Link to Heart Disease

Fasting or non fasting?

Erectile Dysfunction, Cardiovascular Risk and

ERECTILE DYSFUNCTION DIAGNOSIS

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Is there an association between atherosclerosis and chronic venous disease?

Joshua A. Beckman, MD. Brigham and Women s Hospital

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski

Background. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.

Blood Pressure Targets in Diabetes

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Case Study: Chris Arden. Peripheral Arterial Disease

Early Detection of Damaged Organ

Antihypertensive Trial Design ALLHAT

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Arterial Age and Shift Work

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Lipid Management 2013 Statin Benefit Groups

CHOLESTEROL-LOWERING THERAPHY

Introduction. Risk factors of PVD 5/8/2017

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

egfr > 50 (n = 13,916)

Endothelial function is impaired in women who had pre-eclampsia

Using Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O.

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Are Statins an Effective Treatment in Men With Erectile Dysfunction?

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

Estimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure

Correlation of novel cardiac marker

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust

New Paradigms in Predicting CVD Risk

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Causes of death in Diabetes

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

TODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients

Managing the Patient with Erectile Dysfunction: What Would You Do?

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Testosterone and PDE5 inhibitors in the aging male

PULSE WAVE VELOCITY AS A NEW ASSESSMENT TOOL FOR ATHEROSCLEROSIS

Review of guidelines for management of dyslipidemia in diabetic patients

Testosterone Therapy in Men An update

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

How would you manage Ms. Gold

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Pulse wave velocity, augmentation index and arterial age in students

FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

ARTERIAL STIFFNESS ASSESSMENT COMMENTS:

Blood Pressure LIMBO How Low To Go?

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Which CVS risk reduction strategy fits better to carotid US findings?

Estrogens vs Testosterone for cardiovascular health and longevity

Low grade inflammation and cardiovascular disease

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

pulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension

Erectile dysfunction as a predictive factor for coronary artery disease

Study 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

The Clinical Unmet need in the patient with Diabetes and ACS

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

HTA ET DIALYSE DR ALAIN GUERIN

Adherence to a healthy diet in relation to cardiovascular incidence and risk markers: evidence from the Caerphilly Prospective Study

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Current and Future Imaging Trends in Risk Stratification for CAD

Update on CVD and Microvascular Complications in T2D

Transcription:

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health Unit, 1 st Cardiology Department, Athens Medical School, Department of Urology, Hippokration Hospital

Conflict of interests: The authors declare no conflict of interest

Central hemodynamics and prediction of CV events in ED patients Erectile dysfunction Central hemodynamics Study protocol Statistical analysis & results Discussion Conclusions

Erectile Dysfunction (ED) How prevalent is it? 1 in 5 American men Over 30 million American men Over 150 million men worldwide Causes: 90% physical, 10% psychogenic Selvin E, Am Jour of Med 2007(120) 151-157 Sun P, J Urol. 2005 Nov;174(5):1948-52 Mulligan T, Va Med Q. 1991 Spring;118(2):97-9

Erectile Dysfunction (previously known as Impotence) ED affects about 10% of men aged 40-70 and prevalence increases with age ED is common in patients with subclinical or symptomatic coronary artery disease (CAD) ED is considered an early manifestation of a generalized vascular disease and predicts all-cause mortality and cardiovascular (CV) events including CAD, stroke and peripheral artery disease (PAD)

Main causes of ED Cause I nflammatory M echanical P sychological O cclusive vascular T rauma E ndocrine N eurologic C hemical E xtra factors Etiology Prostatitis, urethritis Peyronie s Disease, chordee Depression, performance anxiety, stress, relationship difficulties Arterial: Hypertension, smoking, hyperlipidemia, DM., peripheral vascular disease Venous: venous occlusion due to anatomical or degenerative changes Pelvic fracture, SC injection, penile trauma Hypogonadism, hyperprolactinemia, hypo + hyperthyroidism Parkinson s, multiple sclerosis, spina bifida, pelvic surgery, peripheral neuropathy Anti-HTN, anti-arrhythmics, antidepressants, anxiolytics, antiandrogens, anticonvulsants, alcohol, marijuana, anti-parkinsonic drugs, LHRH analogues Prostatectomy, old age, CRF, cirrhosis

Main causes of ED 1% 6% 5% 3% Vascular Diabetes Medication 15% Medication 40% Vascular Pelvic Surgery, Radiation or Trauma Neurological Causes Endocrine Problems Other 30% Diabetes Goldstein I. Sci Am., Aug 2000;283(2):70-75

Central hemodynamics and prediction of CV events in ED patients Erectile dysfunction Central hemodynamics Study protocol Statistical analysis & results Discussion Conclusions

Central hemodynamics Novel biomarkers Arterial stiffness Carotid-femoral pulse wave velocity-cfpwv (IIa/A) Brachial-ankle pulse wave velocity-bapwv (IIb/B) Central haemodynamics/wave reflections (IIb/B) Central (aortic) pressure Augmentation pressure (measure of the enhancement of central aortic pressure by the reflected pulse wave) Augmentation Index-AIx (augmentation pressure to PP ratio) Vlachopoulos C. Atherosclerosis;241;(2015):507-532

Recommendation for clinical use The role of vascular biomarkers for primary and secondary prevention Vlachopoulos et al. Atherosclerosis 2015, European Society of Cardiology - Position Paper

Central pressures and Augmentation index Direct wave Reflected wave Central pressures do not correspond to brachial pressures due to pressure pulse amplification of a varying degree when moving from the aorta to the periphery Central (aortic, carotid) pressures are pathophysiologically more relevant than peripheral pressures for the pathogenesis of cardiovascular disease

Central hemodynamics and prediction of CV events in ED patients Erectile dysfunction Central hemodynamics Study protocol Statistical analysis & results Discussion Conclusions

Study Protocol Background Established and novel biomarkers are particularly useful in primary or secondary prevention, and since ED is primarily a vascular disease, arterial biomarkers are particularly appealing Central (aortic) blood pressures (BP) more accurately reflect loading conditions of vital organs and thus, should better related to target organ damage and cardiovascular events than peripheral pressures. The purpose of the present study was to investigate whether central hemodynamics predict major adverse cardiovascular events (MACEs) in patients with erectile dysfunction (ED) beyond traditional risk factors.

Study Protocol 398 ED pts (mean age 56 yrs) Sexual Health Inventory for Men (SHIM) Questionnaire 1. How do you rate your confidence that you could get and keep an erection? 2. When you had erections with sexual stimulation, how often were your erections hard enough for penetration (entering your partner)? 3. During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner? 4. During sexual intercourse how difficult was it to maintain your erection to completion of intercourse? 5. When you attempted sexual intercourse, how often was it satisfactory for you? ASSESMENT OF ED Augmentation Index (AIx) was defined as augmented pressure (AP=maximum systolic pressure - pressure at the inflection point) divided by pulse pressure and expressed as percentage AP PP %. Higher values of AIx indicate increased arterial stiffening and wave reflections and vice-versa.

Study Protocol

Central hemodynamics and prediction of CV events in ED patients Erectile dysfunction Central hemodynamics Study protocol Statistical analysis & results Discussion Conclusions

Statistical analysis & results Differences in normal variables: Student t-test Differences in non-normal variables: Mann-Whitney U test Frequency comparison: Pearson chi-square test Free of MACE survival among tertiles estimation: Kaplan-Meier curves and Mantel log-rank test for comparison Central pressures: relative risks (RRs) calculation per 10-mmHg difference & risk estimates were adjusted for age and risk factors AIx: RRs calculation per absolute 10% difference & risk estimates were adjusted for peripheral pressure Subject reclassification: further assessment with net reclassification improvement (NRI), so that case subjects will not be categorized as higher-risk and control subjects will not be categorized as lower-risk, compared to a base model

Statistical analysis & results The mean follow-up time was 6.5 years (range 1-11), during which 29 (7.2%) subjects developed MACE (24 nonfatal, 5 fatal) Of those with CAD events (n=20), 2 were fatal, 4 were myocardial infarction with survival beyond one day and 14 were documented angina pectoris or coronary revascularization Other MACE events were cerebrovascular events (n=6), and new onset of peripheral arterial disease (n=3, 1 fatal)

Statistical analysis & results Baseline clinical characteristics of patients with a MACE and subjects without MACE MACE (n=29) No MACE (n=369) *P value Age (years) 61±6 55±10 <0.001 BMI (Kgr/m 2 ) 27.8±2.7 28.7±4.2 0.23 Total cholesterol, mg/dl 209±34 207±36 0.85 HDL cholesterol, mg/dl 44±8 45±9 0.86 Triglycerides, mg/dl 111 (75-136) 109 (80-131) 0.98 Glucose, mg/dl 107 (86 117) 105 (84 115) 0.54 hscrp, mg/l 1.9 (1.5-2.4) 1.7 (1.3-2.0) 0.43 Total testosterone, ng/ml 4.0 ±0.8 4.5±1.2 <0.05 Hypertension, n (%) 24 (83) 170 (48) <0.001 Hypercholesterolemia, n (%) 16 (55) 212(60) 0.39 Diabetes, n (%) 6 (21) 61(17) 0.37 Smoking, n (%) 16 (55) 187 (53) 0.48 Drug Therapy, n (%) Antihypertenive therapy 20 (69) 156 (42) 0.005 Statins 11 (38) 114 (31) 0.47 IIEF-5 12.6±3 13.2±4 0.46 PSV (cm/s) 29±10 33±9 0.03 BMI: body-mass index; BP: blood pressure; CV: cardiovascular; ED: erectile dysfunction; FRS: Framingham Risk Score; HDL: high density lipoprotein; hscrp: high sensitivity C-reactive protein; MACE: major adverce cardiovascular events; PSV: peak systolic velocity Categorical variables are presented as absolute (relative) frequencies; continuous variables, as mean ±SD or median (interquartile range) PSV was measured in 278 ED patietns (25 with MACE and 253 w/o MACE) *P value: refers to differences between patients with a MACE and subjects without MACE

Statistical analysis & results Peripheral and Central BP characteristics of patients with a MACE and subjects without MACE MACE No MACE *P value (n=29) (n=369) Heart rate (bpm) 69±8 70±7 0.54 Brachial Systolic BP, mmhg 140±17 131±17 0.008 Brachial Diastolic BP, mmhg 84±7 82±8 0.25 Brachial Pulse Pressure, mmhg 56±13 49±13 <0.001 Mean Pressure, mmhg 103±10 100±10 0.27 Aortic Systolic BP, mmhg 130±16 121±16 0.006 Aortic Diastolic BP, mmhg 84±7 83±8 0.57 Aortic Pulse Pressure, mmhg 56±13 48±13 <0.001 Augmentation Index (%) 30±10 24±10 <0.001 BP: blood pressure; MACE: major adverse cardiovascular events; Continuous variables, as mean ±SD *P value: refers to differences between patients with a MACE and subjects without MACE

Statistical analysis & results Outcome and prognostic impact of central hemodynamics The whole population was divided into tertiles according to the brachial and aortic BP level, AIx and AP.

Statistical analysis & results Kaplan-Meier curves for MACE by tertile group of Ao systolic / Ao pulse pressure and AIx significantly associated with MACE significantly associated with MACE significantly associated with MACE

Statistical analysis & results Adjusted HRs for MACEs (for age, cholesterol, smoking history & additionaly for systolic pressure for AIx) Parameters HR (95% CI) Significance (P) Aortic Systolic BP 1.062 (95% CI 1.016 1.117) 0.047 10mmHg difference Aortic Diastolic BP 1.012 (95% CI 0.970 1.050) 0.54 Aortic PP 1.117 (95% CI 1.038 1.153) 0.025 Brachial Systolic BP 1.034 (95% CI 1.004 1.106 0.20 10% absolute increase Brachial PP 1.072 (95% CI 1.024 1.138) 0.036 AIx 1.191 (95% CI 1.056 1.372) 0.01 AIx: augmentation index; BP: blood pressure; PP: pulse pressure

Statistical analysis & results MACE by tertiles of Ao Systolic pressure HR (95% CI) for MACE 1 st tertile <116 mmhg 2nd tertile 116-128 mmhg 3rd tertile >128 mmhg Unadjusted 1 (REF) 1.14 (0.35-3.40) 2.55 (0.95-6.29) Adjusted for age, cholesterol, smoking 1 (REF) 0.95 (0.27-2.78) 1.87 (0.70-4.79) P<0.05 for 3 rd tertile vs 1 st tertile MACE by tertiles of Ao Pulse Pressure HR (95% CI) for MACE 1 st tertile <34 mmhg 2nd tertile 34-42 mmhg 3rd tertile >42 mmhg Unadjusted 1 (REF) 1.49 (0.43-5.30) 4.04 (1.36-10.5) Adjusted for age, cholesterol, smoking 1 (REF) 1.62 (0.46-5.73) 2.76 (0.90-8.56) P<0.01, P<0.05 for 3 rd tertile vs 1 st tertile MACE by tertiles of Augmentation Index HR (95% CI) for MACE 1 st tertile <23 % 2nd tertile 23-31.5 % 3rd tertile >31.5 % Unadjusted 1 (REF) 1.69 (0.37-4.96) 3.95 (1.47-12.5) Adjusted for age, SP, heart rate, cholesterol, smoking 1 (REF) 1.82 (0.65-4.98) 2.84 (0.86-7.40) P<0.01, P<0.05 for 3 rd tertile vs 1 st tertile AIx: augmentation index; SP: systolic pressure; MACE: major adverse cardiovascular events

Central hemodynamics and prediction of CV events in ED patients Erectile dysfunction Central hemodynamics Study protocol Statistical analysis & results Discussion Conclusions

Discussion Clinical implications Central hemodynamics and CV risk Mechanisms Limitations

Central hemodynamics and prediction of CV events in ED patients Erectile dysfunction Central hemodynamics Study protocol Statistical analysis & results Discussion Conclusions

Conclusions Aortic systolic and pulse pressure and aortic augmentation index independently of age and risk factors predicted MACEs The adjusted relationship between AIx/aortic pulse pressure and incident MACEs was consistent Central pressures and wave reflection indices fulfill important criteria for a biomarker to enter the clinical arena as regards investigation of ED patients without known CVD

Thank you for your attention! Tak for din opmærksomhed! Σας ευχαριστώ για την προσοχή σας!